Full TitleA Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma(AMC #075)
The purpose of this study is to find the highest dose of the drug vorinostat that can be given safely with standard chemotherapy in patients with HIV-related diffuse large B-cell lymphoma (DLBCL). Vorinostat is approved for the treatment of another type of lymphoma called cutaneous T-cell lymphoma, but its use for DLBCL is considered investigational.
Patients will receive vorinostat with either rituximab and CHOP therapy (for those with low-risk DLBCL) or vorinostat with rituximab and EPOCH therapy (for patients with high-risk disease). Adding vorinostat to standard therapy may improve the treatment for this type of lymphoma.
Vorinostat may also have a positive effect against HIV and other viruses which can cause lymphoma. Doctors will be monitoring the effect of this treatment on HIV and other viruses in the blood.
This study is for patients who:
- Have previously untreated DLBCL that is positive for the CD20+ protein (the target of rituximab).
- Have HIV infection.
- Are able to be ambulatory for more than half of their normal waking hours.
- Are age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Ariela Noy at 212-639-7423.